Pelthos Therapeutics
Durham, North Carolina, United States · Biotechnology, Health Care, Pharmaceutical
Pelthos Therapeutics Inc. was formerly known as Chromocell Therapeutics Corp. Pelthos Therapeutics specializes in developing treatments for molluscum contagiosum infections. The company is known for its FDA-approved drug ZELSUVMI, which is the first prescription treatment for home use. Pelthos is committed to advancing patient care through innovative therapeutic solutions. It operates as a subsidi
Key facts
- Headquarters
- Durham, North Carolina, United States
- Employees
- 83
- Industries
- Biotechnology, Health Care, Pharmaceutical
- Status
- Public (PTHS)
- Website
- pelthos.com
- Company page
Recent activity at Pelthos Therapeutics
Pelthos Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Nov 2025 | Venture | $18.0M |
| Jul 2025 | Venture | $50.1M |
| Aug 2024 | Venture | $750K |
Leadership
- Melvin Whitehead, Senior Vice President, Operations
- Sai Rangarao, Chief Commercial Officer (CCO)
- John M. Gay, Chief Financial Officer
- Carri Geer, Chief Technology Officer
- Suzie Paulson, Vice President of Human Resources
- Scott Plesha, Chief Executive Officer
Verified email and direct lines for Pelthos Therapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Pelthos Therapeutics in the news
- Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3% - Yahoo Finance (Oct 06, 2026)
- Pelthos Therapeutics Launches to Accelerate Commercialization of Treatment for Molluscum Contagiosum - Dermatology Times (Apr 03, 2024)
- Pelthos Therapeutics Announces Second Quarter 2026 Financial Results - GlobeNewswire (Aug 13, 2026)
- Pelthos Therapeutics Inc. (PTHS) Company Information - Simply Wall Street (Jul 05, 2025)
- FDA-approved berdazimer gel, 10.3% launches to treat molluscum contagiosum - Contemporary Pediatrics (Jul 10, 2025)
- Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain - Yahoo Finance (Mar 31, 2026)
- Zelsuvmi, First At-Home Prescription Gel for Molluscum Contagiosum, Launches in US - Dermatology Times (Jul 10, 2025)
- Pelthos Therapeutics (NYSEAM:PTHS) - Stock Analysis - Simply Wall Street (Jul 27, 2025)
Companies similar to Pelthos Therapeutics
- Timberlyne Therapeutics · Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Santhera Pharmaceuticals · Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Centessa Pharmaceuticals plc · Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Alchemab Therapeutics · Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Journey Therapeutics · Biotechnology, Health Care, Pharmaceutical, Therapeutics
About Pelthos Therapeutics: questions and answers
What does Pelthos Therapeutics do?
Pelthos Therapeutics Inc. was formerly known as Chromocell Therapeutics Corp. Pelthos Therapeutics specializes in developing treatments for molluscum contagiosum infections. The company is known for its FDA-approved drug ZELSUVMI, which is the first prescription treatment for home use. Pelthos is committed to advancing patient care through innovative therapeutic solutions. It operates as a subsidi
Where is Pelthos Therapeutics headquartered?
Pelthos Therapeutics is headquartered in Durham, North Carolina, United States.
How many employees does Pelthos Therapeutics have?
Pelthos Therapeutics has about 83 employees.
Has Pelthos Therapeutics raised funding?
Yes. Fundz has recorded 3 funding events for Pelthos Therapeutics. The most recent, $18.0M, was in Nov 2025.
Who leads Pelthos Therapeutics?
Melvin Whitehead is a Senior Vice President, Operations at Pelthos Therapeutics.
What is the latest news on Pelthos Therapeutics?
On Apr 10, 2026, Pelthos Therapeutics Appoints John M. Gay as Chief Financial Officer
Is Pelthos Therapeutics a public company?
Yes. Pelthos Therapeutics is publicly traded under the ticker PTHS.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy